Medicare Enrolled
Dr. Mays Al-Shaer, M.D.
Internal Medicine · Rhinebeck, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Al-Shaer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Al-Shaer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Al-Shaer
Dr. Mays Al-Shaer is an internal medicine specialist in Rhinebeck, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Al-Shaer performed 6,115 Medicare services across 4,349 unique beneficiaries.
Between the years covered by Open Payments, Dr. Al-Shaer received a total of $4,150 from 42 pharmaceutical and/or device companies across 266 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Al-Shaer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in NY
$4,150 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,115
Medicare services
Top 4% in NY for internal medicine
4,349
Unique beneficiaries
$56
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~322 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Destruction of precancerous skin growths, 2-14 This procedure involves the removal or destruction of two to fourteen precancerous skin lesions. It is performed to eliminate abnormal skin cells that have the potential to develop into cancer. |
1,499 | $6 | $18 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
780 | $72 | $238 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
742 | $93 | $336 |
| Skin biopsy, tangential A procedure to remove a sample of the first identified skin growth for laboratory examination. |
618 | $79 | $277 |
| Destruction of precancerous skin growth, 1 Removal of a single precancerous skin growth. This procedure destroys abnormal skin cells to prevent them from developing into cancer. |
524 | $41 | $175 |
| Destruction of skin growths (warts/lesions), 1-14 This procedure involves the removal or destruction of one to fourteen skin growths. It is a minor surgical intervention performed on the skin surface. |
406 | $93 | $309 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
232 | $120 | $437 |
| Tissue pathology examination, moderate complexity A laboratory test where a pathologist examines tissue samples under a microscope to analyze cellular details. This intermediate complexity procedure involves specialized techniques to identify abnormalities in the tissue. |
216 | $30 | $181 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
155 | $89 | $294 |
| Additional skin growth biopsy Removal of a sample of an additional skin growth for laboratory examination. This code is used for each extra lesion biopsied during the same session. |
146 | $45 | $139 |
| Destruction of 15 or more precancerous skin growths This procedure involves the removal or destruction of fifteen or more precancerous skin lesions. It is performed to treat abnormal skin cells that have the potential to develop into cancer. |
146 | $145 | $433 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
134 | $8 | $11 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
122 | $48 | $150 |
| New patient office visit, 15-29 minutes An initial office visit for a new patient lasting 15 to 29 minutes. This code is used when the total time spent on the date of the encounter meets this duration threshold. |
51 | $49 | $188 |
| Destruction of cancer skin growth, 1.1-2.0 cm Removal of a cancerous skin growth on the trunk, arms, or legs that measures between 1.1 and 2.0 centimeters. |
46 | $154 | $466 |
| Skin tag removal, 1-15 tags This procedure involves the removal of one to fifteen skin tags. It is a minor surgical intervention to excise these benign growths from the skin. |
45 | $51 | $247 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
44 | $1 | $5 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
38 | $10 | $26 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
34 | $8 | $19 |
| Acne surgery A surgical procedure to treat acne. The specific techniques and extent of the surgery are not defined in this general code description. |
33 | $93 | $306 |
| Injection into skin growths, 1-7 A procedure involving the injection of medication into one to seven skin growths. |
31 | $37 | $148 |
| Erythrocyte sedimentation rate (ESR) test A blood test that measures how quickly red blood cells settle in a test tube to detect inflammation in the body. This specific method is performed manually rather than using an automated machine. |
24 | $4 | $17 |
| C-reactive protein test (inflammation marker) A blood test that measures the level of C-reactive protein to detect the presence of infection or inflammation in the body. |
20 | $5 | $13 |
| Removal of noncancer skin growth, 1.1-2.0 cm This procedure involves the surgical removal of a benign skin growth located on the body, arms, or legs. The growth measured between 1.1 and 2.0 centimeters in diameter. |
18 | $149 | $458 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
11 | $13 | $34 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.5% high complexity
13.7% medium
85.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,150
Total received (2018-2024)
Avg $593/year across 7 years
Top 18% in NY for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
266
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,150 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$477
2023
$298
2022
$73
2021
$25
2020
$221
2019
$1,504
2018
$1,553
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$142
E.R. Squibb & Sons, L.L.C.
$107
Helsinn Therapeutics (U.S.), Inc.
$37
GENZYME CORPORATION
$28
UCB, Inc.
$28
Chiesi USA, Inc.
$27
PFIZER INC.
$26
Amgen Inc.
$24
Dermavant Sciences, Inc.
$21
Arcutis Biotherapeutics, Inc.
$19
Incyte Corporation
$19
Top 3 companies account for 60.0% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$643
AbbVie, Inc.
$418
Sun Pharmaceutical Industries Inc.
$309
Lilly USA, LLC
$262
E.R. Squibb & Sons, L.L.C.
$197
Amgen Inc.
$186
Ortho Dermatologics, a division of Bausch Health US, LLC
$178
PFIZER INC.
$174
ABBVIE INC.
$155
LEO Pharma Inc.
$147
Novartis Pharmaceuticals Corporation
$115
DUSA Pharmaceuticals, Inc.
$93
AstraZeneca Pharmaceuticals LP
$93
GENZYME CORPORATION
$86
Dermavant Sciences, Inc.
$85
GlaxoSmithKline, LLC.
$85
AbbVie Inc.
$82
Incyte Corporation
$80
Arcutis Biotherapeutics, Inc.
$76
Galderma Laboratories, L.P.
$74
Janssen Biotech, Inc.
$74
Regeneron Healthcare Solutions, Inc.
$59
Almirall LLC
$51
Endo Pharmaceuticals Inc.
$50
Merck Sharp & Dohme Corporation
$39
Helsinn Therapeutics (U.S.), Inc.
$37
Kowa Pharmaceuticals America, Inc.
$29
UCB, Inc.
$28
Chiesi USA, Inc.
$27
Allergan, Inc.
$25
SANOFI-AVENTIS U.S. LLC
$20
DERMIRA, INC.
$19
Bayer HealthCare Pharmaceuticals Inc.
$19
Aclaris Therapeutics, Inc.
$17
Synergy Pharmaceuticals Inc
$17
Mayne Pharma Inc.
$17
Janssen Pharmaceuticals, Inc
$17
PruGen, Inc. Pharmaceuticals
$16
EPI Health, LLC
$15
ARBOR PHARMACEUTICALS, INC.
$14
Mission Pharmacal Company
$14
Genentech USA, Inc.
$11
Top 3 companies account for 33.0% of all-time payments
Associated products mentioned in payments ›
20% · ABSORICA · ABSORICA (isotretinoin) · ABSORICA LD · ALTRENO · Avar · BLU-U · BREO · BRYHALI · Bensal HP · Bimzelx · COSENTYX · DORYX · DUOBRII · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · EFUDEX · ENSTILAR · ENTRESTO · EPIDUO FORTE · EUCRISA · Edarbi · Enbrel · Erivedge · FARXIGA · FILSUVEZ · Finacea · Humira · ILUMYA · ILUMYA (tildrakizumab-asmn) injection · JANUVIA · JARDIANCE · LITFULO · Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution · Livalo · NASCOBAL · OPZELURA · Otezla · PICATO · Prolia · REMICADE · RETIN-A-MICRO · RHOFADE · RINVOQ · SIVEXTRO · SKYRIZI · SOOLANTRA · STEGLATRO · Seysara · Sotyktu · TALTZ · TRELEGY ELLIPTA · TRULICITY · Tazorac · Tremfya · Trulance · ULTRAVATE · VALCHLOR · VTAMA · XARELTO · XIMINO · Zoryve
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Internal medicine physicians within 10 mi
189
Per 100K population
63.6
County median income
$97,273
Nearest hospital
NORTHERN DUTCHESS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Al-Shaer is a clinical cardiology specialist, with above-average Medicare volume (top 4% in NY), with low-engagement industry engagement in the top 18% of NY peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Al-Shaer experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Al-Shaer performed 1,499 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Al-Shaer receive payments from pharmaceutical companies?
Yes. Dr. Al-Shaer received a total of $4,150 from 42 companies across 266 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Al-Shaer's costs compare to other internal medicine physicians in Rhinebeck?
Dr. Al-Shaer's average Medicare payment per service is $56. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Al-Shaer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Rhinebeck
Browse internal medicine physicians in Rhinebeck ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in NY
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in NY
Which NY internal medicine physicians receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
By company
Sun Pharmaceutical Industries Inc. Payments to Doctors
See all physicians who received payments from Sun Pharmaceutical Industries Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology